This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Zejula
  • /
  • Niraparib in Combination With Pembrolizumab in Pat...
Clinical trial

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)

Read time: 2 mins
Last updated:1st Mar 2016
Identifier: NCT02657889

This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 121 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Study Start Date: March 2016
Estimated Primary Completion Date: May 2018
Estimated Study Completion Date: February 2019

Arm:
- Experimental:
niraparib plus pembrolizumab

Category Value
Date last updated at source 2018-02-12
Study type(s) Interventional
Expected enrolment 121
Study start date 2016-03-01
Estimated primary completion date 2018-05-01

View full details